Table I.

Demographic, Echocardiogaphic, and Pressure-Volume measures among Preserved controls, Hypertensive controls, and subjects with HFPEF

	Preserved	HTN without HF	HFPEF
No. of Subjects	75	89	56
Demographics
Age (years)	67±7	65±12	71±9^{^}
Gender (% Women)	45	18^*	30
SBP (mmHg)	122±10	141±22^*	144±26^*
DBP (mmHg)	73±8	81±13^*	77±16
HR (bpm)	68±9	68±10	69±10
Comorbidities
Hg (mg/dl)	15.0±1.3	14.5±1.7	13.8±2.3^{^}
Diabetes (%)	0	21^*	30^*
eGFR (ml/min)	96±21	94±28	79±26^*^{^}
CHD (%)	0	40^*	64^*
BMI (kg/m²)	24±4	26±3^*	26±4^*
BSA(m²)	1.71±0.17	1.82±0.15^*	1.82±0.18^*
Biomarkers
BNP (pg/ml)	89±98	80±59	561±701^*^{^}
Echo Parameters
LVEDV/BSA (ml/m²)	48±10	49±14	55±17^*^{^}
LVESV/BSA(ml/m²)	17±4	18=1=6	21±9^*^{^}
SV (ml)	52±12	56±17	61±19^*
EF (%)	65±3	64±4	63±6^*
E/E'	7.1±1.6	7.8±2.4	10.0±2.8^*^{^}
LVM/BSA (gm/m²)	86±18	113±25^*	125±43^*^{^}
LVH (%)	12	44^*	63^*
P-V Indices
E_a (mm Hg/ml)	2.2±0.5	2.4±0.8	2.3±0.8
E_es (mmHg/ml)	2.1±0.5	2.1±0.7	1.9±0.8
E_a/E_es	1.1±0.2	1.3±0.3^*	1.3±0.3^*
V₀ (ml)	−27±9	−38±22^*	-42±26*
V₃₀ (ml)	90±21	98±29	109±37
V₃₀/BSA(ml/m²)	53±11	54±15	60±19^*
V₁₂₀ (ml)	34±12	30±14	32±19

P<0.05 vs control,

^{^}

P<0.05 between HTN with and without HF by Bonferroni post hoc test.

Gender and percent with diabetes are analyzed via Chi-Square. SBP-systolic blood pressure, DBP-diastolic blood pressure, BMI-body mass index, Hg-hemoglobin, eGFR-estimated glomerular filtration rate, BMI-body mass index, BNP- B-type natriuretic peptide, EDVI-end diastolic volume index, ESVI-end systolic volume index, SV-stroke volume, EF-ejection fraction, LVM-left ventricular mass, LVH-left ventricular hypertrophy, BSA-body surface area, LVEDP-left ventricular end-diastolic pressure, PV-pressure-volume, E_a-arterial elastance, E_es –End systolic elastance, V₀-estimated ventricular volume at an end-systolic pressure of 0, V₃₀- estimated ventricular volume at an end-systolic pressure of 30, V₁₂₀- estimated ventricular volume at an end-systolic pressure of 120